Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks Kv1.5 channels, for the potential treatment of atrial fibrillation

Current Opinion in Investigational Drugs

Volumn 11, Issue 9, 2010, Pages 1048-1058

  Billman, George E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOFILIUM; DIGOXIN; DOFETILIDE; FLECAINIDE; POTASSIUM CHANNEL KV1.5; SODIUM CHANNEL; SODIUM CHLORIDE; SOTALOL; VERNAKALANT;

ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CIRCUMORAL PARESTHESIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE REFRACTORY PERIOD; HEART RIGHT BUNDLE BRANCH BLOCK; HEART SURGERY; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; LOW DRUG DOSE; NAUSEA; NONHUMAN; POTASSIUM CURRENT; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINUS BRADYCARDIA; SINUS RHYTHM; SNEEZING; TORSADE DES POINTES;

ANIMALS; ANISOLES; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; KV1.5 POTASSIUM CHANNEL; MACACA FASCICULARIS; MALE; POTASSIUM CHANNEL BLOCKERS; PYRROLIDINES; RABBITS; SODIUM CHANNEL BLOCKERS;

EID: 77956239586     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed recitifier K+ current similar to Kv1.5 cloned channel currents. Wang Z, Fermini B, Nattel S CiRC Res 1993 73 6 1061-1076
2. Nortran arrhythmia drug demonstrates oral bioavailability. Nortran Pharmaceuticals Inc PRess Release 2001 June 21
3. RSD1235: A novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs. Nattel S, Blasio E, Beatch GN, Wang WQ euR HeaRt J, 2001, 22, Suppl, Abs P2362.
4. Safety of RSD1235 in a rabbit Purkinje fiber model. Hesketh JC, Beatch GN, Ezrin AM, Johnson BD, Fedida D WORlD CONGR PHaRMaCOl, 2002, 24, July 7-12, Abs 22.12
5. RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodelled atria. Beatch GN, Shinagawa K, Johnson BD, Jung G, Plouvier B, Zolotoy A, Ezrin AM, Walker MJA, Nattel S WORlD CONGR PHaRMaCOl, 2002, 24, July 7-12, Abs 22.11.
6. Safety and pharmacokinetics of RSD1235, a novel atrial fibrillation converting drug, in healthy volunteers. Ezrin A, Grant S, Bell G, Jung G, Clohs L, Johnson B, Kisicki J, Beatch G CaRDiOvasC DRuGs tHeR 2002 16 Suppl 1 Abs P297
7. RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodeled atria. Beatch GN, Shinagawa K, Johnson B, Jung G, Plouvier B, Zolotoy A, Ezrin AM, Walker MJA, Nattel S PaCiNG CliN eleCtROPHYsiOl, 2002, 24, Pt II Abs 698.
8. Cardiome reports dosing of first patient in pivotal phase III atrial arrhythmia studies. Cardiome Pharma Corp PRess Release 2003 August 06
9. Cardiome and Fujisawa sign US$68 million partnership agreement. Cardiome Pharma Corp PRess Release 2003 October 16
10. Electrophysiological mechanism of RSD1235, a new atrial fibrillation converting drug. Beatch GN, Lin S, Hesketh C, Johnson BD, Ezrin AM, Fedida D CiRCulatiON 2003 108 17 Abs 400
11. Future opportunities and innovative therapies for cardiovascular diseases - SMi conference, London, UK. Mazucco RA iDDB MeetiNG RePORt 2003 November 19-20
12. Fujisawa invests $4 million in Cardiome. Cardiome Pharma Corp PRess Release 2004 September 28
13. The novel AF conversion agent RSD1235 terminates EADs and prevents torsade de pointes in a rabbit model. Orth PM, Lynn LM, Yang Y, Hesketh JC, Mak CM, Beatch G, Ezrin AM, Fedida D CiRCulatiON, 2004, 110, 17, Abs 3433.
14. Acute reversal of electrical remodeling and cardioversion of persistent AF by a novel atria-selective antiarrhythmic drug, RSD1235, in goat. Beatch GN, Helmes M, Blaauw Y, Allessie MA CiRCulatiON 2004 110 17 Abs 778
15. Cardiome's pivotal AF study achieves primary endpoint. Cardiome Pharma Corp PRess Release 2004 December 20
16. Cardiome receives US$6 million milestone payment. Cardiome Pharma Corp PRess Release 2005 February 23
17. Presentation material for Merril Lynch healthcare conference. Astellas Pharma Inc COMPaNY WORlD WiDe WeB site 2005 February 10
18. RSD1235 effectively converts atrial fibrillation to sinus rhythm independent of background use of oral rate- or rhythm-control medications. Roy D, Pratt C, Camm Aj, Grant S, Kitt TM, Yan B, Mangal B CiRCulatiON 2006 114 18 Suppl Abs 3697
19. Xention initiates phase I study: XEN-D0101 enters clinical development for atrial fibrillation. Xention Discovery Ltd PRess Release 2009 October 09
20. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN J CaRDiOvasC PHaRMaCOl 2007 50 1 35-40
21. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery. Kowey PR, Roy D, Pratt CM, Schwartz PJ, Dorian P, Mitchell LB, Toft E CiRCulatiON 2007 116 16 Abs 2860
22. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH et al CiRCulatiON 2008 117 12 1518-1525
23. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): Influence of CYP2D6 expression and other factors. Mao ZPL, Wheeler JJ, Clohs L, Beatch GN, Keirns J J CliN PHaRMaCOl 2009 49 1 17-29
24. Merck & Co Inc and Cardiome sign license agreement for vernakalant, an investigational drug for treatment of atrial fibrillation. Merck & Co Inc PRess Release 2009 April 09
25. Cardiome announces that collaboration and license agreement with Merck & Co Inc now effective. Cardiome Pharma Corp PRess Release 2009 May 19
26. Cardiome achieves milestone from collaboration with Merck & Co Inc. Cardiome Pharma Corp PRess Release 2009 July 28
27. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S, Ezrin AM et al J aM COll CaRDiOl 2004 44 12 2355-2361
28. The investigational antiarrhythmic agent RSD1235 is atrially selective in humans. Dorian P, Mangat I, Korley V, Beatch GN, Cvitkovic S, Pinter A CiRCulatiON 2005 112 17 Suppl S Abs 2369
29. Vernakalant (RSD1235) injection converts recent-onset atrial fibrillation to sinus rhythm rapidly and effectively. Vidaillet HJ, Kitt TM, Dickinson G, Mangal B CRit CaRe MeD 2006 34 12 Abs 208
30. Efficacy and safety of RSD1235 injection in the treatment of atrial fibrillation: Combined analysis of two phase III trials. Torp-Pedersen C, Roy D, Pratt C, Camm J, Beatch GN, Kitt T, Yan B, Mangal B euR HeaRt J, 2006, 27, Suppl 1, Abs P5163.
31. Safety and efficacy of vernakalant hydrochloride injection for the conversion of acute atrial fibrillation to sinus rhythm: Subanalysis from an open-label trial. Kavanagh K, Kitt TM, Yan B CRit CaRe MeD, 2007, 35, 12, Abs 309
32. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter. Mao ZL, Gao Y, Kshirsagar S, Keirns J CliN PHaRMaCOl tHeR, 2007, 81, Abs OIII-A-I
33. Efficacy and safety of vernakalant hydrochloride injection (RSD1235) for the conversion of acute atrial fibrillation in patients presenting to the emergency department within 48 hours of onset. Stiell I, Roy D, Pratt C, Dickinson G, Mangal B aNN eMeRG MeD 2007 50 3 Abs 21
34. The conversion of recent-onset atrial fibrillation to sinus rhythm with vernakalant hydrochloride injection: The influence of patients' medical history and baseline characteristics. Rowe BH, Dickinson G, Mangal B, Kitt TM aNN eMeRG MeD 2008 52 4 Abs 22
35. Influence of CYP2D6 genotype on the pharmacokinetics of vernakalant hydrochloride injection (RSD1235), a novel atrial-selective antiarrhythmic. Mao ZL, Clohs L, Wheeler JJ, Beatch GN, Keirns J CliN PHaRMaCOl tHeR, 2008, 83, Abs PII-69.
36. The pharmacokinetics of vernakalant following intravenous administration in healthy volunteers. Erdman K, Lee J, Wang Z, Townsend R, Keirns J CliN PHaRMaCOl tHeR, 2009, 85, Abs PI-88.
37. Vernakalant hydrochloride injection for recent-onset atrial fibrillation; summary from two randomized, controlled trials and one open-label study. Vidaillet HJ, Kavanagh KM, Kitt T, McNutt B, Yan B, Dickinson G, Mangal B J aM COll CaRDiOl 2008 51 10 Abs 1008-101
38. Merck pipeline (as of April 30, 2010). Merck & Co Inc COMPaNY WORlD WiDe WeB site 2010 April 30
39. Announcement of new mid-term management plan. Astellas Pharma Inc PRess Release 2010 May 25
40. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Stiell IG, Roos JS, Kavanagh KM, Dickinson G aM HeaRt J 2010 159 6 1095-1101
41. Investigational Brinavess (vernakalant) for infusion recommended for approval by the CHMP in the European Union (EU) for the rapid conversion of recent onset atrial fibrillation. Merck & Co Inc PRess Release 2010 June 25
42. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Kannel WB, Wolf PA, Benjamin EJ, Levy D aM J CaRDiOl 1998 82 8A 2N-8N
43. Secular trends in incidence of atrial fibrillation in Olmsted County Minnesota, 1980 to 2000, and implications on the projection for future prevalence. Miyaska Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TSM CiRCulatiON 2006 114 2 119-125
44. Atrial fibrillation and stroke in the general Medicare population: A 10-year perspective (1992 to 2002). Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA STRoKE 2006 37 8 1969-1974
45. The clinical and cost-effectiveness of implantable cardioverter defibrillators: A systemic review. Byrant J, Brodin H, Loveman E, Clegg A HealtH teCHNOl assess 2005 9 1-150
46. Molecular physiology of cardiac repolarization. Nerbonne JM, Kass RS PHYsiOl Rev 2005 85 4 1205-1253
47. Role of IKur in controlling action potential shape and contractility in the human atrium: Influence of chronic atrial fibrillation. Wettwer E, Hala O, Christ T, Heubach JF, Dobrev D, Knaut M, Varro A, Ravens U CiRCulatiON 2004 110 16 2299-2306
48. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Feng JL, Wible B, Li GR, Wang ZG, Nattel S CiRC Res 1997 80 4 572-579
49. Vernakalant (RSD1235): A novel, atrial-selective antifibrillatory agent. Fedida D eXPeRt OPiN iNvestiG DRuGs 2007 16 4 519-532
50. The mechanism of atrial antiarrhythmic action of RSD1235. Fedida D, Orth PMR, Chen JYC, Lin SP, Plouvier B, Jung G, Ezrin AM, Beatch GN J CaRDiOvasC eleCtROPHYsiOl 2005 16 11 1227-1238
51. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Eldstrom J, Wang Z, Xu H, Pourrier M, Ezrin A, Gibson K, Fedida D MOl PHaRMaCOl 2007 72 1522-1534
52. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Orth PMR, Hesketh JC, Mak CKH, Yang Y, Lin SP, Beatch GN, Ezrin AM, Fedida D CaRDiOvasC Res, 2006, 70, 3, 486-496.
53. Modeling of high-affinity binding of the novel atrial anti-arrhythmic agent, vernakalant, to Kv1.5 channels. Eldstrom J, Fedida D J MOl GRaPH MODel 2009 28 3 226-235
54. Non-equilibrium gating in cardiac Na+ channels: An original mechanism of arrhythmia. Clancy CE, Tateyama M, Liu HJ, Wehrens XHT, Kass RS CiRCulatiON 2003 107 17 2233-2237
55. Pharmacotherapy options in atrial fibrillation: Focus on vernakalant. Cheng JWN, Rybak I CliN MeD: tHeR, 2009, 1, 215-230.
56. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. Pedersen OD, Abildstrom SZ, Ottesen MM, Rask-Madsen C, Bagger H, Kober L, Torp-Pedersen C euR HeaRt J 2006 27 3 290-295
57. Vernakalant hydrochloride for rapid conversion of atrial fibrillation after cardiac surgery: A randomized, double-blind, placebo controlled trial. Kowey PR, Dorian P, Mitchell B, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E CiRCulatiON: aRRHYtHMia eleCtROPHYsiOl 2009 2 652-659
58. New drugs targeting the cardiac ultra-rapid delayed rectifier current (IRationale, pharmacology and evidence for potential therapeutic value. Ford JW, Milnes JT J CaRDiOvasC PHaRMaCOl 2008 52 2 105-120
59. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel. Gross MF, Castle NA, Zou A, Wickenden AD, Yu W, Spear KL BiOORG MeD CHeM lett, 2009, 19, 11, 3063-3066.
60. Discovery of triarylethanolamine inhibitors of Kv1.5 potassium channel. Beshore DC, Liverton NJ, McIntyre CJ, Claiborne CF, Libby B, Culberson JC, Salata JJ, Regan CP, Lynch JJ, Kiss L, Spencer RH et al BiOORG MeD CHeM lett 2010, 20, 8, 2493-2496
61. Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective Kv1.5 blockers. Lloyd J, Finlay HJ, Vacarro W, Hyunh T, Kover A, Bhandaru R, Yan L, Atwal K, Conder ML, Jenkins-West T, Shi H et al BiOORG MeD CHeM lett 2010, 20, 4, 1436-1439.
62. Development of selective Kv1.5 blockers: Development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4- (4-methoxyphenyl)-2- imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia. Blass BE, Fensome A, Trybulski E, Magolda R, Gardell SJ, Liu K, Samuel M, Feingold I, Huselton C, Jackson CM, Djandjighian L et al J MeD CHeM, 2009, 52, 21, 6531-6534.
63. Clinical efficacy and safety of vernakalant compared with amiodarone for intravenous conversion of recent onset atrial fibrillation. Camm JA, Capucci A, Hohnloser S, Torp-Pedersen C, Van Gelder I, Butterfield N, Mangal B, Beatch G aNN Meet HeaRt RHYtHM sOC 2010 May 15
64. Oral vernakalant for the prevention of atrial fibrillation recurrence post-cardioversion. Torp-Pedersen C, Karpenko Y, Raev D, Kaik J, Dickinson G, Mangal B, Beatch GN euR HeaRt J, 2009, 30, Suppl, Abs 2780.
65. Oral vernakalant (RSD1235-SR) prevents recurrence of atrial fibrillation following cardioversion. Torp-Pedersen C, Raev D, Georgiev P, Navratil J, Nagy A, Blomstrom P, Karpenko Y, Faulkner J, Dickinson G, Beatch GN euR HeaRt J, 2007, 28, Suppl, Abs P2538.
66. Vernakalant. Cardiome Pharma Corp COMPaNY COMMuNiCatiON 2010 July 30
67. New antiarrhythmic drugs for treatment of atrial fibrillation. Dobrev D, Nattel S laNCet 2010 375 9725 1212-1223
68. Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG CaRDiOvasC Res, 2003, 58, 1, 32-45.